default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

SK, Sanofi begins P1 clinical trials for next-gen pneumococcal vaccine

Lee Han-soo  Published 2018.12.12  17:22  Updated 2018.12.12 17:22

공유
default_news_ad2

SK Bioscience and Sanofi have started to conduct the U.S. phase 1 clinical trial for the next-generation pneumococcal vaccine after receiving U.S. Food and Drug Administration approval for their investigational new drug (IND) application.

SK Chemical, a parent company of SK Bioscience, concluded a joint development and sales contract for a next-generation pneumococcal vaccine with Sanofi Pasteur in 2014, with the aim of advancing into the global market.

Under the agreement, Sanofi Pasteur will cooperate with SK Bioscience to develop the entire pneumococcal vaccine development process, including licensing and marketing.

According to Data Monitor Healthcare, a global market research firm, the pneumococcal vaccine market is worth about 5.2 trillion won ($4.6 billion) in the U.S., Japan, and five EU countries in 2016. The firm expects that the market will grow to 7 trillion won by 2025.

“The company’s goal in creating a premium vaccine that will lead the global market through next-generation innovations is gradually coming to fruition,” SK Bioscience CEO Ahn Jae-yong said. “We will continue to improve human health through innovative vaccine technology.”

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch